Risultati per: Lesioni ulcerative dei genitali

This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacological management of moderate-to-severe ulcerative colitis (UC).

This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacological management of moderate-to-severe ulcerative colitis (UC).

Annals of Internal Medicine, Ahead of Print.

We performed an updated systematic review and network meta-analysis to inform the 2024 American Gastroenterological Association (AGA) Clinical Guidelines on the management of moderate-to-severe ulcerative colitis (UC).

A man in his 70s presented with 2 enlarging, painless nodular lesions on the forehead and right cheek. Histopathological examination showed extensive dermal collection of lymphocytes, histiocytes, and macrophages. What is your diagnosis?

New England Journal of Medicine, Volume 391, Issue 12, Page 1119-1129, September 26, 2024.

These 2 randomized clinical trials compare the efficacy and safety of risankizumab vs placebo during an induction trial and a maintenance trial in patients with ulcerative colitis.

The inflammatory bowel diseases of ulcerative colitis and Crohn disease are chronic inflammatory conditions of the intestine. The estimated incidence of ulcerative colitis is 15 per 100 000 person-years and the prevalence is 400 per 100 000 in North America. Despite advances to medical management, nearly 1 in 5 patients with ulcerative colitis will be hospitalized and approximately 7% will require a colectomy within 5 years of diagnosis. The health care cost of ulcerative colitis has steadily risen over the past 2 decades, and the per-person average cost was $9000 in 2021. The high cost of ulcerative colitis largely has been attributed to the escalating cost of medical therapy.

Message Barrier healing represents a novel therapeutic target in ulcerative colitis (UC), although its assessment remains challenging and lacks standardisation. This exploratory study evaluates the ability of ultra-high magnification endocytoscopy to guide tissue sampling and drive automated quantification of tight junction (TJ) proteins to assess intestinal barrier integrity and predict major adverse outcomes (MAOs). 34 UC patients in clinical remission prospectively underwent assessment with endocytoscopy and machine learning-enabled intestinal barrier protein evaluation. The combination of endocytoscopy with Claudin-2 expression showed promise in accurately predicting MAOs over 12 months. This integrative approach holds promise in identifying deep healing and enhancing treat-to-target strategy in UC. Detail Barrier healing is attracting fresh attention as a therapeutic target in UC.1 2 However, its evaluation is subjective and not standardised. It has generally depended on probe permeability with considerable variability, thus highlighting an unmet need for novel…

Acute severe ulcerative colitis (ASUC), characterised by bloody diarrhoea and systemic inflammation, is associated with a significant risk of colectomy and a small risk of mortality. The landmark trial of cortisone in 1955 was pivotal for two reasons: first, for establishing the efficacy of a drug that remains a first-line therapy today and, second, for producing the first set of disease severity criteria and clinical trial endpoints that shaped the subsequent ASUC trial landscape. Trials in the 1990s and at the turn of the millennium established the efficacy of infliximab and ciclosporin, but since then, there has been little progress in drug development for this high-risk population. This systematic review evaluates all interventional randomised controlled trials (RCTs) conducted in patients hospitalised with severe UC. It provides an overview of the efficacy of treatments from past to present and assesses the evolution of trial characteristics with respect to study populations, eligibility criteria and study designs over time. This review details ongoing RCTs in this field and provides a perspective on the challenges for future clinical trial programmes and how these can be overcome to help deliver novel ASUC therapies.

We read with interest the recent paper by Vich Vila et al, which discussed alterations in the metabolome of patients with inflammatory bowel disease (IBD).1 Here, the authors described >300 molecules that were differentially abundant in the faeces of 424 patients with IBD compared with 255 healthy controls, analysed with liquid chromatography with tandem mass spectrometry as well as genome-wide association analysis. Of note, decreased faecal L-urobilin and increased levels of the sphingolipid lactosyl-N-palmitoyl-sphingosine were not only key markers associated with IBD, but furthermore including their ratio improved the accuracy of disease prediction above age, sex, body mass index and faecal calprotectin levels. IBD-associated intestinal dysbiosis is characterised by reduced microbial diversity, increases in facultative anaerobes and a decrease in obligately anaerobic producers of short-chain fatty acids, as well as the accumulation of primary unconjugated bile acids and depletion of secondary bile acids.2 The physiological…